Synonym
Galanthamine Hydrobromide; Galantamine HBr; Galantamine HBr; Nivalin; Razadyne; Reminyl; Nivaline; Razadyne; NSC 100058; NSC100058; NSC-100058;
IUPAC/Chemical Name
(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol hydrobromide
InChi Key
QORVDGQLPPAFRS-XPSHAMGMSA-N
InChi Code
InChI=1S/C17H21NO3.BrH/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17;/h3-6,12,14,19H,7-10H2,1-2H3;1H/t12-,14-,17-;/m0./s1
SMILES Code
CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
368.27
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Li W, Zhou Y, Zhao N, Hao B, Wang X, Kong P. Pharmacokinetic behavior and
efficiency of acetylcholinesterase inhibition in rat brain after intranasal
administration of galanthamine hydrobromide loaded flexible liposomes. Environ
Toxicol Pharmacol. 2012 Sep;34(2):272-9. doi: 10.1016/j.etap.2012.04.012. Epub
2012 May 3. PubMed PMID: 22613079.
2: Riemann D, Gann H, Dressing H, Müller WE, Aldenhoff JB. Influence of the
cholinesterase inhibitor galanthamine hydrobromide on normal sleep. Psychiatry
Res. 1994 Mar;51(3):253-67. PubMed PMID: 8208872.
3: Yamboliev I, Mutafova-Yambolieva V, Mihailova D. Gastrointestinal loss of
galanthamine hydrobromide in rats in-situ. J Pharm Pharmacol. 1993
Aug;45(8):763-5. PubMed PMID: 7901379.
4: Snorrason E, Stefánsson JG. Galanthamine hydrobromide in mania. Lancet. 1991
Mar 2;337(8740):557. PubMed PMID: 1671920.
5: Mihailova D, Yamboliev I, Zhivkova Z, Tencheva J, Jovovich V. Pharmacokinetics
of galanthamine hydrobromide after single subcutaneous and oral dosage in humans.
Pharmacology. 1989;39(1):50-8. PubMed PMID: 2587617.
6: Mihailova D, Velkov M, Zhivkova Z. In vitro metabolism of galanthamine
hydrobromide (Nivalin) by rat and rabbit liver homogenate. Eur J Drug Metab
Pharmacokinet. 1987 Jan-Mar;12(1):25-30. PubMed PMID: 3609070.
7: Mihailova D, Yamboliev I. Pharmacokinetics of galanthamine hydrobromide
(Nivalin) following single intravenous and oral administration in rats.
Pharmacology. 1986;32(6):301-6. PubMed PMID: 3725886.
8: Cozanitis D, Dessypris A, Nuuttila K. The effect of galanthamine hydrobromide
on plasma ACTH in patients undergoing anaesthesia and surgery. Acta Anaesthesiol
Scand. 1980 Jun;24(3):166-8. PubMed PMID: 6255718.
9: Cozanitis DA. [Galanthamine hydrobromide : a substitute for eserine sulphate
(physostigmine) in the treatment of the cerebral effects of anti-cholinergic
substances]. Nouv Presse Med. 1978 Dec;7(45):4152. French. PubMed PMID: 745952.
10: Cozanitis DA. Galanthamine hydrobromide, a longer acting anticholinesterase
drug, in the treatment of the central effects of scopolamine (Hyoscine).
Anaesthesist. 1977 Dec;26(12):649-50. PubMed PMID: 603022.
11: Cozanitis DA, Toivakka E. Treatment of respiratory depression with the
anticholinesterase drug galanthamine hydrobromide. Anaesthesia. 1974
Sep;29(5):581-4. PubMed PMID: 4433018.
12: Cozanitis DA, Rosenberg P. Preliminary experiments with galanthamine
hydrobromide on depressed respiration. Anaesthesist. 1974 Jul;23(7):302-5. PubMed
PMID: 4458502.
13: Cozanitis DA. Galanthamine hydrobromide versus neostigmine. A plasma cortisol
study in man. Anaesthesia. 1974 Mar;29(2):163-8. PubMed PMID: 4819071.
14: Cozanitis DA, Nuuttila K, Karhunen P, Baraka A. Changes in cardiac rhythm
with galanthamine hydrobromide. Anaesthesist. 1973 Oct;22(10):457-9. PubMed PMID:
4766907.
15: Cozanitis D, Toivakka E, Dessypris A. Electroencephalographic and blood
chemistry responses to galanthamine hydrobromide in epileptic volunteers.
Anaesthesist. 1973 Jan;22(1):31-3. PubMed PMID: 4632556.
16: Cozanitis DA, Halttunen P, Edgren J. A cinebronchographic study demonstrating
the effect of galanthamine hydrobromide on conscious asthmatic volunteers.
Anaesthesist. 1972 Feb;21(2):63-6. PubMed PMID: 5027567.
17: Pereira MA, Pena AA, Cardoso A, Freitas MJ, Ferro FN. [Galanthamine
hydrobromide in the reversion of nondepolarizing neuromuscular block]. Rev Bras
Anestesiol. 1972 Jan-Mar;22(1):10-9. Portuguese. PubMed PMID: 4261779.
18: Cozanitis DA, Toivakka E. A comparative study of galanthamine hydrobromide
and atropine-neostigmine in conscious volunteers. Anaesthesist. 1971
Nov;20(11):416-21. PubMed PMID: 5126442.
19: Cozanitis DA. Experiences with galanthamine hydrobromide as curare
antagonist. Anaesthesist. 1971 Jun;20(6):226-9. PubMed PMID: 4256926.
20: Costantini D, Josi G, Signore L. [Clinical and electrocardiographic tests of
the use of galanthamine hydrobromide as a de-curarizing drug]. Acta Anaesthesiol.
1971 Jan-Feb;22(1):75-83. Italian. PubMed PMID: 5109626.
